Friday, 29 May 2026 A-TANGO Consensus Conference The A-TANGO Score: A Novel Tool for Risk Stratification and Clinical Endpoints in ACLF Rajiv Jalan (UCL) and Cornelius Engelmann (Charité) Track Hub 6 - Cirrhosis & Complications 10:00 – 10:30
Wednesday, 27 May 2026 MICROB-PREDICT Consensus Conference Microbiome-based mechanisms and biomarkers for improved patient stratification & therapeutic response prediction in decompensated cirrhosis and ACLF Jansen Room 15:30 – 18:30 h View agenda (catering included) This is a satellite event and…
DECISION members at EASL Congress: Talks Wednesday, 27 May
The EASL General Assembly will take place on Friday, 29 May 2026, from 18:45 to 20:00 during EASL Congress 2026 in Barcelona. The meeting will be held in person in the Mondelli Room. Please note that an active EASL Membership…
We are excited to announce the launch of the call for nominations and applications for three prestigious awards: the EASL Community Award 2026, the EASL Emerging Leader Award 2026, and the EASL Excellence in Liver Care Award 2026. These awards…
This ambitious collaboration between academic, clinical, and industry partners aims to transform how liver diseases are diagnosed and treated by developing innovative and cost-effective tools for early diagnosis and personalized care, with the goal of improving patient outcomes.
The ambition of the LiverScreen Consortium has been realised with the screening of more than 30.000 participants from the general population across 9 different European Countries and the development & validation of the Liver Risk Score, bringing forward significant new…
DECISION strives to better understand the pathophysiology of decompensated cirrhosis leading to acute-on-chronic liver failure (ACLF) at the systems level by taking advantage of already existing large and clinically well-characterized patient cohorts. The ultimate goal is to significantly reduce mortality…
22 European institutions join forces in MICROB-PREDICT to improve the prevention and treatment of chronic liver disease (cirrhosis). We aim to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional…
A-TANGO strives to increase the survival rate with G-TAK – a novel combinatorial therapy, and to decrease the burden on the national healthcare systems, which is caused by a large percentage of patients who never recover fully and require long-term care.